Researchers at the University of Kentucky have investigated an experimental drug called MW150, which targets the p38α MAPK pathway associated with brain inflammation. The study, published in the journal Alcohol, indicates that MW150 may reduce inflammatory markers during alcohol withdrawal, potentially easing symptoms linked to alcohol use disorder. The drug is currently being studied for its effects on mild to moderate Alzheimer's disease.
Caleb Bailey, PhD, a co-author of the study, noted that the findings provide biological plausibility for MW150's potential to mitigate neuroinflammation during alcohol withdrawal. He emphasized the need for follow-up experiments to confirm these effects in animal models of alcohol use disorder.
Dr. Amy Swift, deputy chief medical officer at Silver Hill Hospital, commented on the significance of the research, stating that while detoxification is a critical first step in treating alcohol use disorder, it does not address the disorder itself. She suggested that medications aimed at improving brain health could fill a gap in early treatment.
Bailey reiterated that no level of alcohol consumption is beneficial for physical health and that minimizing alcohol intake remains the best strategy for health. He also highlighted the importance of understanding how MW150 and similar compounds interact with alcohol as research progresses.